Astrazeneca (AZN) Cash from Investing Activities (2009 - 2026)

Astrazeneca has reported Cash from Investing Activities for 18 years, with the latest figure at -$2.9 billion in Q2 2026.

• On a quarterly basis, Cash from Investing Activities fell 38.14% year-over-year to -$2.9 billion in Q2 2026; TTM through Jun 2026 was -$8.2 billion, a 34.59% decrease from a year earlier, with the FY2025 full-year figure at -$6.8 billion, up 14.69% from the prior year.
• Cash from Investing Activities was -$2.9 billion for Q2 2026 at Astrazeneca, down from -$1.8 billion in the prior quarter.
• The five-year high for Cash from Investing Activities was -$168.0 million in Q1 2022, with the low at -$2.9 billion in Q2 2026.
• Average Cash from Investing Activities over 5 years is -$1.6 billion, with a median of -$1.5 billion recorded in 2024.
• The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities sank 641.67% in 2023, then surged 48.07% in 2025.
• Over 5 years, Cash from Investing Activities stood at -$800.0 million in 2022, then soared by 35.0% to -$520.0 million in 2023, then sank by 127.12% to -$1.2 billion in 2024, then fell by 22.44% to -$1.4 billion in 2025, then tumbled by 101.38% to -$2.9 billion in 2026.
• The last three Cash from Investing Activities figures came in at -$2.9 billion (Q2 2026), -$1.8 billion (Q1 2026), and -$1.4 billion (Q4 2025), per Business Quant data.